OTHER GROUP COMPANIES
market

SEBI issues a "warning letter" to Aurobindo Pharma over USFDA audit row

At the upcoming board meeting, the corporation has been instructed to present the warning letter to the board of directors.

June 27, 2022 2:59 IST | India Infoline News Service

On June 27, the pharmaceutical company Aurobindo Pharma told the stock markets that it had received a "warning letter" from the Securities and Exchange Board of India (SEBI) over the controversy surrounding the US Food and Drug Administration (USFDA) audit at its Hyderabad facility.


Hyderabad, India's HITEC City serves as the corporate headquarters for the worldwide pharmaceutical manufacturing business Aurobindo Pharma Limited. The business produces both active medicinal components and generic medications.


In the next board meeting, the firm has been requested to present the warning letter to the board of directors, according to the regulatory filing.

OPEN A DEMAT ACCOUNT & Get
FREE Benefits Worth 5,000

FEATURED ARTICLE

BLOGS

Open Demat Account
  • 0

    Per Order for ETF & Mutual Funds Brokerage

  • 20

    Per Order for Delivery, Intraday, F&O, Currency & Commodity